Corgenix Medical Corporation Stockholders Encouraged to Contact Securities Law Firm about the definitive merger agreement to be acquired by Orgentec Diagnostika

NEW YORK, Sept. 3, 2014 /PRNewswire/ -- Securities lawyers at Dunnam & Dunnam are investigating potential claims against the Board of Directors of Corgenix Medical Corporation (OTC:CONX) in connection with the definitive merger agreement of Corgenix Medical to Orgentec Diagnostika.  Concerned CONX investors are encouraged to contact attorney Hamilton Lindley by clicking here.

The law firm is investigating because the total assets and revenue multiples are below the averages of comparable transactions, according to Bloomberg.  Additionally, the stock closed at $0.461 three weeks ago.  Corgenix shareholders will receive only $.027 in cash for each share of common stock they own, in a transaction valued at approximately $16 million. 

Dunnam & Dunnam has significant experience representing shareholders in securities lawsuits nationwide. CONX stockholders – or anyone with knowledge about this situation – should contact lawyer Hamilton Lindley at [email protected] with questions, toll free at (844) 702-2990 or visit http://www.dunnamlaw.com/CONX.

SOURCE Dunnam & Dunnam